Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 11/13/2017
Entire Document
 

Picture 3


 

subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Investor/Media Contact

Lucy Li, Ph.D.

+1 781-801-1800

ir@beigene.com

media@beigene.com 

 

___________________________

i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.

 



© 2016 BeiGene. All Rights Reserved.